GAMMA Investing LLC Raises Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

GAMMA Investing LLC lifted its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 34.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 736 shares of the medical instruments supplier’s stock after acquiring an additional 188 shares during the quarter. GAMMA Investing LLC’s holdings in LeMaitre Vascular were worth $68,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Conestoga Capital Advisors LLC lifted its stake in LeMaitre Vascular by 0.4% in the 2nd quarter. Conestoga Capital Advisors LLC now owns 1,941,501 shares of the medical instruments supplier’s stock valued at $159,747,000 after buying an additional 8,584 shares in the last quarter. Vanguard Group Inc. grew its position in LeMaitre Vascular by 0.3% during the first quarter. Vanguard Group Inc. now owns 1,553,834 shares of the medical instruments supplier’s stock valued at $103,112,000 after acquiring an additional 4,964 shares during the period. Congress Asset Management Co. MA increased its position in LeMaitre Vascular by 12.0% during the 1st quarter. Congress Asset Management Co. MA now owns 666,083 shares of the medical instruments supplier’s stock worth $44,201,000 after purchasing an additional 71,411 shares in the last quarter. Driehaus Capital Management LLC lifted its holdings in shares of LeMaitre Vascular by 52.2% during the 2nd quarter. Driehaus Capital Management LLC now owns 264,217 shares of the medical instruments supplier’s stock valued at $21,740,000 after acquiring an additional 90,573 shares in the last quarter. Finally, Summit Creek Advisors LLC boosted its position in shares of LeMaitre Vascular by 0.6% in the first quarter. Summit Creek Advisors LLC now owns 229,936 shares of the medical instruments supplier’s stock worth $15,259,000 after buying an additional 1,435 shares during the period. 84.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

LMAT has been the subject of several research analyst reports. Cantor Fitzgerald started coverage on LeMaitre Vascular in a research note on Tuesday. They set a “neutral” rating and a $96.00 target price for the company. Lake Street Capital started coverage on shares of LeMaitre Vascular in a research report on Friday, August 2nd. They set a “buy” rating and a $105.00 price objective for the company. JMP Securities boosted their target price on LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a research report on Tuesday, August 20th. Barrington Research reaffirmed an “outperform” rating and issued a $92.00 price objective on shares of LeMaitre Vascular in a research note on Friday, September 20th. Finally, StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Tuesday, August 27th. Three analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $94.67.

LeMaitre Vascular Trading Down 1.0 %

Shares of NASDAQ:LMAT opened at $91.24 on Wednesday. LeMaitre Vascular, Inc. has a 1 year low of $44.27 and a 1 year high of $93.32. The firm has a fifty day moving average price of $88.42 and a 200 day moving average price of $81.05. The stock has a market capitalization of $2.05 billion, a PE ratio of 60.42, a P/E/G ratio of 2.45 and a beta of 0.88.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. LeMaitre Vascular had a return on equity of 12.41% and a net margin of 18.33%. The business had revenue of $55.85 million for the quarter, compared to the consensus estimate of $54.98 million. During the same period last year, the business earned $0.37 EPS. The firm’s revenue was up 11.4% compared to the same quarter last year. On average, sell-side analysts forecast that LeMaitre Vascular, Inc. will post 1.85 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, August 29th. Shareholders of record on Thursday, August 15th were given a $0.16 dividend. The ex-dividend date was Thursday, August 15th. This represents a $0.64 annualized dividend and a yield of 0.70%. LeMaitre Vascular’s dividend payout ratio is 42.38%.

Insider Transactions at LeMaitre Vascular

In related news, Director David B. Roberts sold 3,063 shares of LeMaitre Vascular stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total transaction of $251,380.41. Following the sale, the director now directly owns 14,114 shares of the company’s stock, valued at $1,158,335.98. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 10.79% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.